Little-known Biotech Stock Up 149%? This little-known biotech stock, Core One Labs (CLABD) was ranked #1 by CanninBot last week. But what happened next?
Last Wednesday, CanninBot discovered a profitable trade opportunity with Vancouver-based Core One Labs (CLABD) when it was trading at only $2.00/share. Last night, the stock was valued at $4.99/share for a mind-blowing 149.5% return in 5 days!
Related: Cannin’s Top 3 Cannabis Stocks for July
What is CanninBot and How did it Identify this Opportunity?
CanninBot uses machine learning to evaluate 450 cannabis stocks based on the 10 best technical indicators. You’ll receive daily alerts with a ranking for the 20 strongest stocks, for that specific day, allowing you the best opportunity to make serious potential gains.
What is Core One Labs?
Core One Labs is a biotech company focused on bringing psychedelic medicine to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. This psychedelic stock seems like it was a great investment last week – but will this stock continue to gain momentum?
Related: Up Over 80% this Week – Is Core One Labs a Buy?
Core One Labs Inc. operates as a biotechnology research and technology life sciences company in the United States and Canada. The company focuses on bringing psychedelic medicines to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. The company manufactures CannaStrips, which are cannabis-infused strips, as well as produces oils, distillates, and resins. It also offers consulting services for cultivation, extraction, and manufacturing, as well as financing, nursery, and cultivation services; and holds real estate properties and equipment. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019.
Market Opportunity for Core One Labs
The global antidepressant drug market was valued at $13.7 billion in 2016 and is projected to grow to $15.9 billion by 2023. This is a compound annual growth rate (CAGR) of 2.1% from 2017-2023. These figures include treatments for MDD, obsessive-compulsive disorder and anxiety. For the 300 million people around the globe suffering from a major depressive disorder (MDD), the prescription of antidepressant medication is, in the majority of cases, the first line of therapy.
Related: Science Behind Using Psychedelics To Treat Mental Health and Addiction Is Compelling
One hundred million of those diagnosed with MDD are said to suffer from treatment-resistant depression (TRD). This accounts for approximately 33% of MDD cases. An individual is diagnosed with TRD after they are observed to have failed to sufficiently respond to a course of antidepressants within a specified period.
According to a study published in the Journal of Clinical Psychiatry, TRD costs employers upwards of $48 billion each year in the US alone. This cost is a result of direct increases in health care costs for the employer and both a decrease in productivity/increase in absenteeism of employees who suffer from TRD.
Core One Labs (CLABD) Stock Performance for July 14th:
– Primary Exchange: Greys
– Score: Strong
– Open: 3.9500
– High: 4.4920
– Low: 3.5500
– Close: 4.4909
– Volume: 32336
Who are the Experts Behind Cannin.com?
Since 2017, Cannin has been on a mission to help our members profit from investing in cannabis stocks. Cannin’s global team of analysts, software engineers, and industry veterans provide the tools and information to capitalize on this rapidly growing industry.
Related: Hemp Stock Quotes | Marijuana Stock Quotes
In fact, 78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the last 3 years.
Little-Known Biotech Stock Up 149%
About Cannin Investment Group: Your Psychedelic Stocks Experts
Cannin is your trusted resource for psychedelic stocks. Our global team of experts evaluates all emerging psychedelic stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best psychedelic stock investments for 2021.
Use Cannin as your resource for:
Is it too late to invest in psychedelic stocks? No! This is the perfect time to invest.
Are you looking to buy stock in the best psychedelic companies for 2021? Interested in emerging penny psychedelic stocks? We can help.
Are you interested in psychedelic stocks like MindMed, Compass Pathways or Revive Therapeutics?
Predict price movements of stocks several hours in advance with our proprietary algorithmic stock trading software.
- +30% Gains in 2020
- +49.8% Gains in 2019
- 108% Backtested since 2012
We’re so confident you’ll love our algotrading pot stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best psychedelic stocks – we’ll show you how at cannin.com.
